OBJECTIVE:To evaluate a regimen of inhaled Technosphere insulin (TI) plus insulin degludec in adults with type 1 diabetes, who prestudy were predominately using either an automated insulin delivery (AID) system or multiple daily insulin injections (MDI) with continuous glucose monitoring. RESEARCH DESIGN AND METHODS:At 19 sites, adults with type 1 diabetes were randomly assigned to TI plus insulin degludec (N = 62) or usual care (UC) with continuation of prestudy insulin delivery method (N = 61) for 17 weeks. RESULTS:Prestudy, AID was used by 48% and MDI by 45%. Mean ± SD HbA1c was 7.57% ± 0.97% at baseline and 7.62% ± 1.06% at 17 weeks in the TI group and 7.59% ± 0.80% and 7.54% ± 0.77%, respectively, in the UC group (adjusted difference 0.11%, 95% CI -0.10 to 0.33, P value for noninferiority = 0.01). HbA1c improved from baseline to 17 weeks by >0.5% (5.5 mmol/mol) in 12 (21%) in the TI group and in 3 (5%) in the UC group and worsened by >0.5% (5.5 mmol/mol) in 15 (26%) in the TI group and in 2 (3%) in the UC group. The most common TI side effect was a brief cough; eight participants discontinued TI due to side effects. CONCLUSIONS:In adults with type 1 diabetes, HbA1c after 17 weeks with a regimen of TI and degludec was noninferior to UC, which consisted predominately of either AID or MDI. TI should be considered an option for people with type 1 diabetes, particularly those who are motivated to further reduce postprandial hyperglycemia.
OBJECTIVE:In many individuals, type 2 diabetes (T2D) remains poorly controlled despite taking multiple glucose-lowering therapies. Several studies have demonstrated that endogenous hypercortisolism is prevalent among these individuals. We tested whether cortisol-directed therapy improves their glycemic control. RESEARCH DESIGN AND METHODS:In this prospective, multicenter, double-blind study, 136 individuals with T2D (hemoglobin A1c [HbA1c] 7.5%-11.5% [58-102 mmol/mol] on multiple medications) and hypercortisolism (by dexamethasone suppression test) were randomized 2:1 to the glucocorticoid receptor antagonist mifepristone (300-900 mg once daily; n = 91) or placebo (n = 45) for 24 weeks, with stratification by presence/absence of an adrenal imaging abnormality. The primary end point was the change in HbA1c. Secondary end points included changes in glucose-lowering medications, weight, and waist circumference and safety. RESULTS:Mean baseline HbA1c in the study cohort was 8.55% (69.9 mmol/mol). At 24 weeks, the least squares mean (LSM) difference from placebo in HbA1c was -1.32% (95% CI -1.81 to -0.83; P < 0.001). Participants receiving mifepristone experienced reductions in body weight and waist circumference (placebo-adjusted LSM differences of -5.12 kg [95% CI -8.20 to -2.03] and -5.1 cm [-8.23 to -1.99], respectively). Of participants on mifepristone, 46% discontinued therapy, compared with 18% on placebo. Adverse events with mifepristone (>10% of participants) included hypokalemia, fatigue, nausea, vomiting, headache, peripheral edema, diarrhea, and dizziness, consistent with mifepristone's known tolerability profile. Increases in blood pressure also occurred. CONCLUSIONS:In individuals with inadequately controlled T2D and hypercortisolism, cortisol-directed medical therapy with mifepristone reduced HbA1c, with a manageable tolerability profile.
Objective: To compare the efficacy of enabling ‘Activity feature’ 60-minutes (AF-60) or 30-minutes (AF-30) before prolonged exercise vs. automated mode (Auto) in adults and adolescents with type 1 diabetes wearing the Omnipod® 5 System. Research Design and Methods: In this three-way crossover study, 38 participants (age 30±15 years, BMI 24.7±4.1 kg/m², HbA1c 7.5±0.9% [58±11 mmol/mol]) from the extension phase of the pivotal trial of the Omnipod 5 System underwent a 70-minute treadmill session at 64-76% HRmax in a post-meal-absorptive state under each condition. Auto mode was resumed after exercise, and glycemia and insulin delivery metrics were examined in the 4-hour post-exercise period. Results: The percent of participants that developed hypoglycemia during exercise did not differ significantly between Auto (42%) and AF-60 (29%, p=0.34) or AF-30 (24%, p=0.14). However, AF-60 and AF-30 reduced insulin delivery compared to Auto in the hour before (p<0.001) and during exercise (p<0.001). There was also a favorable attenuation in glucose drop during exercise when comparing Auto (-57±-35 mg/dL) with AF-60 (-44±-33mg/dL, p=0.02) and AF-30 (-36±-34 mg/dL, p=0.01). In the post-exercise period, glycemia and insulin delivery were comparable. Conclusions: Enabling Activity feature either 60- or 30-minutes before exercise reduced insulin delivery and attenuated glucose drops relative to Auto mode, but hypoglycemia incidence was not different across the three conditions. These findings support the use of the Omnipod 5 System for exercise but highlight the importance of using additional strategies, such as earlier use of Activity feature and/or carbohydrate intake to further reduce hypoglycemia risk.
Objective: Despite the use of multiple glucose-lowering medications, a significant fraction of individuals with type 2 diabetes (T2D) do not meet glycemic targets. This prospective, observational study assessed the prevalence of hypercortisolism, a potential contributing factor to inadequate glucose control (NCT05772169). Research Design and Methods: Individuals with T2D and HbA1c 7.5–11.5% (58–102 mmol/mol) on ≥2 glucose-lowering medications with or without micro-/macrovascular complications or taking multiple blood pressure-lowering medications were screened with a 1-mg dexamethasone suppression test (DST). Common causes for false-positive DSTs were excluded. The primary endpoint was the prevalence of hypercortisolism, defined as post-DST cortisol >1.8 μg/dL (50 nmol/L). Characteristics associated with hypercortisolism were assessed using multiple logistic regression. The percentage and characteristics of participants with hypercortisolism and adrenal imaging abnormalities were also assessed. Results: Post-DST cortisol was unsuppressed in 252/1057 participants (prevalence 23.8%; 95% confidence interval, 21.3 to 26.5). Hypercortisolism prevalence was 33.3% in participants with cardiac disorders and 36.6% in those taking ≥3 blood pressure-lowering medications. Adrenal imaging abnormalities were reported in 34.7% of participants with hypercortisolism. Use of SGLT2 inhibitors (odds ratio [OR], 1.558), maximum-dose GLP-1 receptor agonists (OR, 1.544), tirzepatide (OR, 1.981), or a higher number of blood pressure-lowering medications (OR, 1.390), older age (OR, 1.316), body mass index <30 kg/m2 (OR, 1.639), non-Latino/Hispanic ethnicity (OR, 3.718), use of fibrates (OR, 2.676) or analgesics (OR, 1.457) were associated with higher prevalence (all P<0.03). Conclusions: Hypercortisolism was associated with hyperglycemia in approximately one quarter of individuals with inadequately controlled T2D despite multiple medications.